|Articles|March 13, 2023
Establishing and Maintaining Phase-Appropriate Regulatory Starting Materials Designation from Development to Commercial Launch Secures Successful New Drug Development
Author(s)Wuxi
WuXi Sta outlines clear guidance on phase appropriate RSM designation and adaptive RSM strategy for the overall API development roadmap. These solutions will mitigate both quality and regulatory risks, thus increasing the chance of success in IND and NDA filing.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
Batch Certification for New Manufacturing Technologies: The Qualified Person Role in a Digital Environment
2
Drug Digest: Closing the Gap in Modern Process Control and Automation for QC/QA
3
Why Pharma’s AI Agents Need Smaller, Domain-Specific Models First
4
How a “Plan, Prevent, Prove” Approach Helps Avoid Facility and Equipment Problems
5
